Page 297 - Haematologica April 2020

PBSC with ATG vs. BM
ease (aGvHD) and (extensive) cGvHD, as well as a lower incidence of relapse (IR) and better overall survival (OS) in the subgroup of patients with late-stage disease.3 Further,
the only phase III trial performed in patients given grafts from HLA-matched unrelated donors (MUD) showed that patients randomized to the BM group had a lower inci-
AB
Multivariate Cox model P=0.75 Univariate log-rank P=0.13
CD
Multivariate Cox model P=0.89 Univariate log-rank P=0.06
E
Multivariate Cox model P=0.64 Univariate Gray P=0.05
cGvHD in MSD F
Multivariate Cox model P=0.01 Univariate Gray P=0.02
Multivariate Cox model P=0.68 Univariate Gray P=0.99
Multivariate Cox model P=0.45 Univariate log-rank P=0.78
Figure 1. Comparison of outcomes in bone marrow (BM) patients without anti-thymocyte globulin (ATG) and in those given peripheral blood (PB) stem cells with ATG (the dotted line shows the PBSC with ATG curve adjusted for relevant covariates) in the cohort of patients receiving grafts from HLA-identical sibling donor (MSD). (A) Overall survival (OS), P=0.13. (B) Leukemia-free survival (LFS), P=0.065. (C) Incidence of relapse (RI), P=0.0496. (D) Non-relapse mortality (NRM), P=0.989. (E) chronic graft-versus-host disease (cGvHD), P=0.0186. (F) GvHD-free and relapse-free survival (GRFS), P=0.782.
haematologica | 2020; 105(4)
1139